Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study
Started May 29, 2020
369
Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
Started December 9, 2019
397
A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Started December 8, 2019
346
Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Started November 21, 2019
334
Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT)
Started September 23, 2019
358
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Started September 23, 2019
295
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Started June 20, 2019
276
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Started June 20, 2019
283
The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL
Started June 14, 2019
328
The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL
Started June 9, 2019
347
Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-label, Registration Directed Phase 2 Study
Started June 4, 2019
394
Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study
Started June 4, 2019
336